Replies to post #8764 on Momenta Pharmaceuticals, Inc. (MNTA)

[vinmantoo]

If the orange book patents on Copaxone expire on May 24, 2014, why would one expect that generics would be launched only by mid 2015? Obviously, the FDA has something to say about the generics, but excluding that, there seems to be a disconnect.

[DewDiligence]

Quiz answer:

US district court rulings on the two patent challenges to Copaxone by Momenta Pharmaceuticals Inc. (Nasdaq: MNTA) and Sandoz Inc. and by Mylan Inc. (NYSE: MYL) and India's Natco Pharma Ltd. could come at any time.

This is misleading insofar as the two cases have been consolidated into one.